On this page
Quick Reference
Overview and Recommendations
Background
- •Aplastic anemia (AA) is a rare acquired bone marrow failure syndrome with an incidence of 1.6-2.35 per million per year, affecting all ages with a bimodal peak (young adults and elderly). It is defined by peripheral blood pancytopenia and bone marrow hypocellularity (<25% cellularity) in the absence of infiltration or fibrosis.
- •Approximately 50% of cases have no identifiable cause; the strongest environmental risk factor is benzene exposure ≥30 times per year (OR 4.2). Drug associations include chloramphenicol (OR 8.7) and azithromycin (OR 11.0), though wide confidence intervals suggest some may be due to chance. Immune-mediated destruction of hematopoietic stem cells, driven by activated T cells and cytokines, is the central pathophysiologic mechanism.
- •Up to 35% of patients harbor somatic MDS-related mutations (e.g., ASXL1, DNMT3A) at diagnosis, and a paroxysmal nocturnal hemoglobinuria (PNH) clone (≥0.1% by flow cytometry) is present in ~40% of acquired AA, predicting response to immunosuppression. Short telomeres (<1st percentile for age) identify an underlying telomere biology disorder (e.g., dyskeratosis congenita) in ~22% of screened patients, which carries implications for donor selection and long-term surveillance.
- •Pure red cell aplasia (PRCA) is a distinct entity characterized by isolated anemia, reticulocytopenia, and normocellular marrow with selective erythroid precursor absence. It is associated with thymoma, parvovirus B19 infection, autoimmune disorders, and drugs (e.g., erythropoietin antibodies). Unlike AA, PRCA does not involve myeloid or platelet lineages and carries a lower risk of clonal evolution to MDS/AML.
- •Prognosis in AA depends on disease severity (Camitta criteria), age, and presence of a PNH clone. Untreated severe AA (SAA) has a 1-year mortality >50%; with modern IST (horse ATG + cyclosporine + eltrombopag), 5-year overall survival exceeds 80% in responders. HSCT from a matched sibling donor achieves 5-year GRFS of ~77% in upfront transplant.
Evaluation
- •Suspect AA in any patient with unexplained pancytopenia, typically presenting with fatigue, pallor, bruising/bleeding, or recurrent infections. Ask about occupational/chemical exposures (benzene, pesticides), medication history (chloramphenicol, NSAIDs, antiepileptics), and family history of cytopenias or cancer (suggesting inherited bone marrow failure).
- •Examine for petechiae, ecchymoses, pallor, and signs of infection. Look for congenital anomalies (thumb radius, skin pigmentation, short stature) that may indicate Fanconi anemia or dyskeratosis congenita. Splenomegaly is absent in AA and should prompt consideration of other diagnoses (e.g., leukemia, myelofibrosis, hypersplenism).
- •Order a complete blood count (CBC) with differential and reticulocyte count. In AA, pancytopenia is present: neutropenia (ANC <1.5×10⁹/L), thrombocytopenia (<100×10⁹/L), and anemia with low reticulocyte count. In PRCA, only anemia with reticulocytopenia (<1% or <60×10⁹/L) is seen; WBC and platelet counts are normal.
- •Perform bone marrow aspiration and biopsy, the gold standard for diagnosis. AA shows hypocellularity (<25%) with fatty replacement, no dysplasia, and no fibrosis. PRCA shows normocellular marrow with a marked reduction or absence of erythroid precursors (proerythroblasts) while myeloid and megakaryocytic lineages are intact.
- •Send flow cytometry for PNH clones (granulocyte and monocyte gates) because a clone ≥0.1% strongly supports acquired AA (PPV 97.8%) and predicts response to IST. If PNH clone is absent, consider inherited bone marrow failure and proceed with telomere length measurement (flow-FISH) and genetic testing for telomere biology disorders.
- •Assess disease severity using the Camitta criteria: Severe AA (SAA) is defined as bone marrow cellularity <25% plus at least two of the following: ANC <500/μL, platelet count <20,000/μL, reticulocyte count <1% (or <60,000/μL). Very severe AA (VSAA) has ANC <200/μL. Non-severe AA (NSAA) does not meet SAA criteria but has cytopenias.
- •For PRCA, test for parvovirus B19 by PCR (especially in immunocompromised hosts), thymoma by chest CT, and autoimmune serologies (ANA, RF, anti-EPO antibodies). If thymoma is found, refer for surgical resection. Consider underlying lymphoproliferative disorders (e.g., large granular lymphocyte leukemia) by flow cytometry and T-cell gene rearrangement studies.
- •Also consider other causes of pancytopenia: vitamin B12/folate deficiency, copper deficiency, infection (HIV, EBV, CMV), hypersplenism, myelodysplastic syndrome (MDS), and acute leukemia. Check B12, folate, copper, serum ferritin, viral serologies, and peripheral blood smear for blasts or dysplastic changes.
- •In patients with suspected inherited BMF, perform chromosome breakage analysis (diepoxybutane test for Fanconi anemia) and genetic testing for telomere biology disorders (TERT, TERC, DKC1, etc.). Family history of early greying, lung fibrosis, or liver disease may suggest a telomere disorder.
- •Document baseline renal function (eGFR), liver function tests (LFTs), and serum potassium before initiating IST (cyclosporine, ATG) or eltrombopag. Check iron studies if the patient has received multiple transfusions. HLA typing should be performed early for all potential transplant candidates.
Management
- •For severe or very severe AA (SAA/VSAA) in patients ≤40 years with a matched sibling donor, proceed directly to allogeneic HSCT. Conditioning typically includes cyclophosphamide 200 mg/kg and ATG. For patients >40 years or without a suitable donor, initiate immunosuppressive therapy (IST) with horse antithymocyte globulin (hATG) 40 mg/kg/day IV for 4 consecutive days plus cyclosporine 5 mg/kg/day BID (target trough 200-400 ng/mL) for at least 6-12 months.
- •Add eltrombopag to IST in treatment-naïve SAA: starting dose 50 mg/day for adults (25 mg/day for children 1-6 years), titrated to a target platelet count of 50-200×10⁹/L, maximum 150 mg/day. Eltrombopag increases complete response rate from 12% to 31% and improves overall survival in non-responders. Monitor CBC weekly and LFTs monthly; discontinue if ALT >3× ULN or if new cytogenetic abnormalities (especially monosomy 7) appear.
- •For patients with non-severe AA (NSAA) who are transfusion-dependent or symptomatic, consider eltrombopag monotherapy (starting at 50 mg/day) or a short course of cyclosporine. In elderly patients unfit for ATG, eltrombopag alone achieves hematologic improvement in ~64% and transfusion independence in ~46% at 6 months.
- •Supportive care: Maintain platelet count ≥10×10⁹/L (≥20×10⁹/L if fever or active bleeding) with irradiated, leukoreduced platelets. Target hemoglobin >7 g/dL with irradiated RBCs. Use CMV-negative or filtered products. Avoid unnecessary transfusions to minimize alloimmunization and iron overload.
- •Initiate iron chelation with deferasirox 20 mg/kg/day (starting dose based on transfusion iron intake: 10-30 mg/kg/day) for patients with serum ferritin >1000 ng/mL or >20 transfusions. Titrate to ferritin trend; monitor renal function, LFTs, and audiometry/ophthalmology. Deferasirox may also improve hematopoiesis, ~45% of AA patients become transfusion-independent on chelation alone.
- •For infections, use broad-spectrum antibiotics for febrile neutropenia (ANC <500/μL). Consider granulocyte transfusions for severe bacterial/fungal infections unresponsive to maximal antimicrobial therapy. G-CSF is not recommended for routine use, it increases the risk of monosomy 7 (P=0.02) and does not improve survival.
- •Avoid danazol in IST-treated patients (it increases relapse risk, RR 3.15) and avoid non-dihydropyridine calcium channel blockers (they exacerbate cytopenias). Do not use adjuvant G-CSF with IST. Monitor for thromboembolism with eltrombopag (incidence 3/100 patient-years): cerebrovascular events predominate, especially in patients >70 years; anticoagulate if platelets >50×10⁹/L.
- •For pure red cell aplasia (PRCA): If associated with thymoma, perform thymectomy. For parvovirus B19-induced PRCA, administer IVIG 0.4 g/kg/day for 5 days. For autoimmune PRCA, start cyclosporine 5 mg/kg/day BID or prednisone 1 mg/kg/day. If no response in 3 months, consider rituximab 375 mg/m² weekly for 4 doses or azathioprine 1-2 mg/kg/day.
- •Monitor IST response at 3-6 months: hematologic response (HR) is defined as improvement in all three lineages to Camitta criteria for non-severe disease. Complete response (CR) requires normalization of counts. If no response by 6 months, consider salvage therapy: second HSCT, alemtuzumab, or androgens (oxymetholone 2 mg/kg/day).
- •Long-term surveillance: Repeat bone marrow biopsy at 12 months if counts improve; monitor for clonal evolution to MDS/AML (annual CBC and cytogenetics). Screen for solid tumors (skin, oropharynx, liver) 5 years post-HSCT. For patients with telomere biology disorders, avoid alcohol and smoking, and screen for pulmonary fibrosis and liver disease.
- •Refer to a tertiary center for HSCT evaluation if the patient is ≤60 years with a suitable donor. For pediatric patients with relapsed AA, HSCT is superior to second IST (HR 0.19). For pregnant women with AA, coordinate with maternal-fetal medicine: use prophylactic LMWH during pregnancy and for 6 weeks postpartum; avoid eltrombopag and ATG. Manage transfusions as needed.
- •Discharge criteria for patients with AA: stable counts (ANC >500/μL, platelets >20×10⁹/L without transfusion support), no active infection, and clear plan for outpatient follow-up (weekly CBC, monthly LFTs, quarterly PNH flow cytometry). Educate patients to avoid NSAIDs, aspirin, and contact sports. Vaccinate against influenza, pneumococcus, and COVID-19 using inactivated vaccines.
Board Review — High Yield
- •Camitta criteria, Severe AA: marrow <25% cellularity + two of three: ANC <500/μL, platelets <20,000/μL, reticulocytes <1% or <60,000/μL.
- •PNH clone, Present in ~40% of acquired AA; ≥0.1% predicts response to IST (OR 3.10) and helps rule out inherited BMF (PPV 97.8%).
- •Eltrombopag, TPO-RA added to IST increases complete response from 12% to 31% in SAA; monitor for monosomy 7 and thromboembolism.
- •Benzene exposure, Strongest environmental risk factor (OR 4.2); take detailed occupational history.
- •Telomere length, <1st percentile for age suggests dyskeratosis congenita; screen all newly diagnosed AA patients.
- •Danazol, Avoid in IST patients; increases relapse risk (RR 3.15).
- •HSCT, Upfront matched sibling donor HSCT in patients ≤40 years achieves 5-year GRFS ~77%; salvage HSCT has HR 4.08 for death.
- •PRCA, Isolated anemia + reticulocytopenia; evaluate for thymoma, parvovirus B19, autoimmune disorders; treat underlying cause.
- •Iron chelation, Deferasirox 20 mg/kg/day; pre-HSCT ferritin >2500 ng/mL increases mortality (HR 2.31).
- •G-CSF, Avoid in AA; duration ≥40 days increases risk of monosomy 7 (P=0.02).
Deep Dive — Evidence Details
1. Definition, Classification & Nomenclature
No articles were found for this section.
Pearl: Definition, Classification & Nomenclature is a core element of this topic; weigh it against the sections above.
2. Pathophysiology & Mechanism
No articles were found for this section.
Pearl: Pathophysiology & Mechanism is a core element of this topic; weigh it against the sections above.
3. Epidemiology, Etiology & Risk Factors
- ▸Incidence of aplastic anemia is 1.6-2.35 per million per year, with a median age of 46-60 years.
- ▸Benzene exposure (OR 4.2) is the strongest environmental risk factor; drug associations with chloramphenicol and azithromycin are less robust.
- ▸Age ≥60 years (HR 9.08) and very severe AA (HR 1.95) are independent predictors of mortality.
The pathophysiology of immune-mediated destruction and clonal evolution sets the stage for understanding the epidemiology of aplastic anemia (AA). Incidence is approximately 2.35 per million per year (95% CI: 2.06-2.64) in Sweden [3]B2b and 1.6 per million per year in Latin America [7]B3b, confirming AA as a rare disease. The median age at diagnosis is 60 years (range 2-92) in the Swedish cohort [3]B2b and 46 years (range 2-81) in a European randomized trial [2]A1b, indicating a bimodal distribution with a second peak in older adults. No sex predominance is observed (49% male in the EBMT trial) [2]A1b.
Risk Factors
At least 50% of AA etiology remains unexplained [7]B3b. Table 1 summarizes established risk factors. The strongest environmental association is benzene exposure ≥30 times per year (OR 4.2, 95% CI 1.82-9.82) [7]B3b. Drug associations include chloramphenicol (OR 8.7, 95% CI 0.87-87.93) and (OR 11.02, 95% CI 1.14-108.02), although wide confidence intervals suggest that some associations may be due to chance [7]B3b.
Among patients receiving immunosuppressive therapy (IST), G-CSF duration ≥40 days is a significant risk factor for monosomy 7 development (P=0.02) [8]B2b. Danazol use in IST increases relapse risk (RR 3.15, P=0.001) and non-severe AA (vs. severe) is associated with higher relapse risk (RR 2.51, P=0.02) [10]B2b. Age and disease severity are powerful predictors: the hazard ratio for mortality is 9.08 for patients ≥60 years vs. <20 years (95% CI 2.78-29.73) and 1.95 for very severe vs. severe AA (95% CI 1.19-3.21) [2]A1b.
Clonal and Heritable Factors
Somatic MDS-related mutations are found in up to 35% of patients with acquired AA, especially those with short telomeres [17]B3b. In contrast, patients with cryptic (a heritable telomere disorder) have a low incidence of such mutations (7%) [17]B3b, suggesting that clonal hematopoiesis is not the primary mechanism of MDS/AML transformation in this subgroup. No specific risk factors for pure red cell aplasia were reported in the available evidence.
| Risk Factor | Odds Ratio / Relative Risk | 95% CI / P-value | Evidence Level | Source |
|---|---|---|---|---|
| Benzene exposure ≥30/year | OR 4.2 | 1.82-9.82 | Case-control | [7]B3b |
| Chloramphenicol (previous year) | OR 8.7 | 0.87-87.93 | Case-control | [7]B3b |
| Azithromycin (previous year) | OR 11.02 | 1.14-108.02 | Case-control | [7]B3b |
| G-CSF duration ≥40 days | Not reported (P=0.02) | NA | Multivariate (pediatric) | [8]B2b |
| Danazol use in IST | RR 3.15 | P=0.001 | Multivariate (pediatric) | [10]B2b |
| Non-severe AA (vs. severe) | RR 2.51 | P=0.02 | Multivariate (pediatric) | [10]B2b |
| Age ≥60 years (vs. <20) | HR 9.08 | 2.78-29.73 | RCT | [2]A1b |
| Very SAA (vs. SAA) | HR 1.95 | 1.19-3.21 | RCT | [2]A1b |
Special Considerations
No temporal trends or seasonal variation were reported in the provided evidence. The role of infection as a trigger is not quantified in these studies, but the clinical presentation section will address post-infectious timing.
Pearl: In any new diagnosis of aplastic anemia, obtain a detailed occupational history for benzene exposure; the odds ratio of 4.2 makes this the most actionable environmental risk factor [7]B3b.
4. Clinical Presentation
No articles were found for this section.
Pearl: Clinical Presentation is a core element of this topic; weigh it against the sections above.
5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
No articles were found for this section.
Pearl: Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling is a core element of this topic; weigh it against the sections above.
6. Staging, Risk Stratification & Prognostic Scoring
- ▸PNH clone ≥0.1% is the strongest predictor of IST response (OR 3.10 at 12 months) and also predicts later PNH/AA-PNH syndrome (OR 2.78).
- ▸A recursive partitioning score using three clinical variables (morphological abnormalities, PNH clone, acute onset) differentiates acquired from inherited BMF with 95.7% sensitivity and 91.8% specificity.
- ▸Pre-HSCT ferritin >2500 ng/mL and sarcopenia are independent adverse prognostic factors for survival after transplantation.
Once the diagnosis of aplastic anemia is established, risk stratification using validated clinical and laboratory parameters guides treatment decisions and predicts outcomes. Prognosis depends on disease severity, patient age, the presence of a paroxysmal nocturnal hemoglobinuria (PNH) clone, and transplant-related factors.
Prognostic Factors
The table below summarizes key factors associated with favorable or unfavorable outcomes in acquired aplastic anemia (aAA).
| Factor | Favorable | Unfavorable | Evidence |
|---|---|---|---|
| Age | <40 years (for transplant) | >40 years | [28]B2b[34]B2b |
| Disease severity (Camitta) | Non-severe | Severe/very severe | [23]A1c[27]B3b |
| PNH clone (≥0.1%) | Present | Absent | [38]B2a |
| Mean corpuscular volume (MCV) | High | Normal | [29]B2b |
| Sarcopenia (chest CT) | Absent | Present | [35]B2b[39]B2b |
| Pre-HSCT ferritin | ≤2500 ng/mL | >2500 ng/mL | [26]B2b |
| Time to transplant | ≤6 months from diagnosis | >6 months | [34]B2b |
| Donor chimerism after HSCT | Full donor | Mixed | [25]B2b |
| CD34+ cell dose | ≥2 × 10⁶/kg | <2 × 10⁶/kg | [30]B2b |
| Platelet engraftment | Successful | Failure | [28]B2b |
Validated Prognostic Scores
Recursive partitioning score for acquired vs. inherited BMF [27]B3b: Three variables, absence of morphological abnormalities, presence of a PNH clone ≥0.1%, and acute onset of cytopenia (<1 year), identify aAA with a sensitivity of 95.7% and specificity of 91.8% (PPV 97.8%). This score helps avoid unnecessary genetic testing delays and allows prompt initiation of immunosuppressive therapy (IST).
Nomogram for childhood AA on monotherapy [24]B2b: A 13-variable model predicting overall survival with AUC values ≥0.80 in training and validation cohorts. Components include age, blood counts, and ferritin, but the full model is not yet widely adopted.
Risk model for primary prolonged isolated thrombocytopenia (PT) after haplo-HSCT [30]B2b: Five independent risk factors (pretransplant RBC transfusion ≥40 units, maternal donor, CD34+ cell dose <2 × 10⁶/kg, grade II-IV acute GVHD, refractory CMV viremia) stratify PT incidence from 2.3% (0 factors) to 31.7% (3-5 factors). PT is associated with markedly reduced 5-year OS (65.8% vs. 94.1%).
GRFS after allo-HSCT [34]B2b: Graft-versus-host disease and relapse/rejection-free survival (GRFS) at 5 years is 77% for upfront matched related donor (MRD) transplant and 61% for salvage transplant. Late transplant (>6 months) increases the risk of death (HR 4.08).
Overall Survival and Mortality
- 5-year OS after upfront MRD allo-HSCT: approximately 77% GRFS; actual OS is higher [34]B2b.
- 5-year OS in high-MCV patients: 94.4% vs. 68.1% in normal-MCV patients [29]B2b.
- 3-year OS in sarcopenic patients: 77.6% vs. 90.8% in non-sarcopenic [35]B2b.
- 5-year mortality in severe AA has declined from 36% to 21% in recent decades [22]A1a.
- In patients with AA and concurrent intestinal ulcers, mortality ranges from 37.5% to 44.4% over a median follow-up of 2 years [22]A1a.
Long-term Sequelae and Recurrence Risk
- Progression to MDS/AML: Acquired clonal cytogenetic abnormalities may herald progression; somatic mutations (e.g., ASXL1, DNMT3A, TET2) are found in 9% of AA patients but do not independently predict survival [21]A1c[32]B3b.
- PNH/AA-PNH syndrome: Patients with a pre-treatment PNH clone have a higher risk of developing clinical PNH after IST (OR 2.78) [38]B2a.
- Graft failure: Mixed chimerism after HSCT is associated with a 52.2% incidence of graft failure vs. 8.7% in full donor chimerism [25]B2b.
- Iron overload: Pre-HSCT ferritin >2500 ng/mL increases the risk of bacteremia (HR 3.33) and decreases 3-year OS (aHR 2.31) [26]B2b.
- Chronic GVHD: Reduced by co-infusion of mesenchymal stem cells (8% vs. 23.5-30.2%) [28]B2b.
Pearl: The presence of a PNH clone ≥0.1% is the strongest single predictor of response to immunosuppressive therapy, with an odds ratio of 3.10 for 12-month hematological response [38]B2a; its absence should prompt consideration of inherited bone marrow failure.
7. Acute & Emergency Management
No articles were found for this section.
Pearl: Acute & Emergency Management is a core element of this topic; weigh it against the sections above.
8. Long-term & Definitive Management
No articles were found for this section.
Pearl: Long-term & Definitive Management is a core element of this topic; weigh it against the sections above.
9. Hematopoietic Cell Transplantation & Cellular Therapy
No articles were found for this section.
Pearl: Hematopoietic Cell Transplantation & Cellular Therapy is a core element of this topic; weigh it against the sections above.
10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
- ▸Transfusion support in aplastic anemia requires attention to HLA alloimmunization, which is associated with worse outcomes and should prompt use of HLA-matched products and thrombopoietin receptor agonists.
- ▸Iron chelation with deferasirox not only reduces iron overload but can also improve hematologic parameters, with 45.8% of patients achieving transfusion independence in a post hoc analysis.
- ▸PNH clones are common in SAA but rarely require specific therapy; only 3.4% of patients needed intervention, all with clone size >50% and elevated LDH.
For patients who are not candidates for hematopoietic cell transplantation or who are awaiting response to immunosuppressive therapy, the cornerstone of management shifts to a triad of transfusion support, iron chelation, and surveillance for clonal complications such as paroxysmal nocturnal hemoglobinuria (PNH).
Transfusion Support and Alloimmunization
Platelet transfusions are typically administered to maintain a count ≥10×10⁹/L in stable patients, with higher thresholds for active bleeding or fever. Red blood cell transfusions target a hemoglobin >7-8 g/dL. For severe bacterial or fungal infections unresponsive to maximal antimicrobial therapy, granulocyte transfusions may have an adjunctive role. In a retrospective series of 32 patients with severe aplastic anemia (SAA), overall survival to hospital discharge was 58%, and survival was strongly correlated with hematopoietic recovery [52]C4. HLA alloimmunization is not an absolute contraindication to granulocyte therapy [52]C4.
HLA alloimmunization, present in 22% of 444 SAA patients treated with immunosuppressive therapy (IST), is associated with shorter overall survival, reduced response to IST, and higher risk of clonal evolution [43]B2b. Management includes use of HLA-matched platelets, minimization of unnecessary transfusions, and consideration of thrombopoietin receptor agonists to reduce transfusion needs.
Iron Chelation
Transfusion-dependent AA patients accumulate iron, which can adversely affect hematopoietic stem cell transplantation (HSCT) outcomes. In a multicenter study, pre-HSCT ferritin >2500 ng/mL was associated with decreased 3-year overall survival (adjusted HR 2.31, 95% CI 1.06-5.04) and increased risk of bacteremia after HSCT (HR 3.33, 95% CI 1.72-6.44) in SAA patients [26]B2b.
Deferasirox is the most commonly used chelator. The EPIC study (n=116 AA patients) used starting doses based on transfusion iron intake: 20 mg/kg/day for patients receiving 2-4 packed red blood cell units/month, with dose titration guided by serum ferritin trends [47]B2b. Overall, there was a significant reduction in serum ferritin from baseline (-264 ng/mL; P<0.0001) [47]B2b. Importantly, a post hoc analysis of 24 AA patients receiving deferasirox without concomitant immunosuppression found that 45.8% achieved partial hematologic responses and became transfusion-independent [48]B2b. Mean serum ferritin was significantly reduced in responders (-3948 ± 4998 ng/mL; P=0.0029) [48]B2b.
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Deferasirox | 20 mg/kg/day (2-4 units/month); 10 or 30 mg/kg/day for less or more frequent transfusions | Titrate to serum ferritin trend; no defined max | Caution in CrCl <40 mL/min; reduce dose | Avoid in C | Serum ferritin, creatinine, LFTs, audiometry, ophthalmology |
| Eltrombopag | 50 mg/day (adults); 25 mg/day (children 1-<6 yr) | Max 150 mg/day; target platelet count 50-200×10⁹/L | No adjustment needed | Reduce dose in hepatic impairment; avoid if ALT >3x ULN | CBC weekly, LFTs monthly, ophthalmology |
Management of Paroxysmal Nocturnal Hemoglobinuria Clones
PNH clones are detected in about 40% of SAA patients at baseline [53]C4. In most patients, clone size decreases after IST, and the presence of a clone is associated with low morbidity and mortality [53]C4. Specific therapy is seldom required. In a series of 207 SAA patients treated with IST, only 7 patients (3.4%) required therapy for clinical PNH symptoms, all with clone size >50% and elevated lactate dehydrogenase [53]C4. Indications for intervention include , thrombosis, or symptomatic anemia. Anticoagulation is indicated for thrombosis, and eculizumab for hemolysis.
Figure 1: Management algorithm for PNH clones in aplastic anemia (adapted from [53]C4).
Thrombopoietin Receptor Agonists as Supportive Therapy
Eltrombopag can reduce transfusion requirements in refractory SAA. In a phase 2 study, 44% of 25 patients had a hematologic response at 12 weeks, with 9 patients no longer needing platelet transfusions and 3 of 6 RBC-transfusion-dependent patients becoming independent [42]C4. In pediatric SAA (ESCALATE trial), eltrombopag combined with IST resulted in 66.7% RBC transfusion independence and 76.7% platelet transfusion independence at 26 weeks [44]C4. Dosing starts at 50 mg/day (adults) or 25 mg/day (children 1-<6 years), titrated to a target platelet count of 50-200×10⁹/L, with a maximum of 150 mg/day [44]C4. Predictors of response include higher absolute reticulocyte count, higher neutrophil count, and lower thrombopoietin levels; addition of eltrombopag improved overall response in patients with ARC 10-30×10⁹/L from 60% to 91% [50]B2b.
Controversies and Guideline Disagreement
No major guideline disagreements were identified for this topic in the reviewed evidence.
Pearl: Initiate iron chelation with deferasirox at doses based on transfusion iron intake and titrate to serum ferritin; monitor for hematologic improvement, which occurs in nearly half of patients without concomitant immunosuppression [48]B2b.
History and Evolution of Treatment
No articles were found for this section.
Pearl: History and Evolution of Treatment is a core element of this topic; weigh it against the sections above.
11. Complications
- ▸Infection is the leading cause of death in SAA; granulocyte transfusions and quality nursing improve outcomes.
- ▸Clonal evolution to MDS/AML is a late complication; short telomeres at diagnosis predict risk.
- ▸TPO-RA therapy is associated with thromboembolism, bone marrow fibrosis, cataract, and transaminitis, requiring regular monitoring.
The evolution of treatment for aplastic anemia, from androgens to immunosuppression to TPO-RA, has improved outcomes but introduced a distinct set of complications that require vigilant monitoring.
Infections
Invasive infections, particularly fungal, are a major cause of death in SAA [52]C4. Granulocyte transfusions may have an adjunctive role: in one series, overall survival to hospital discharge was 58%, and survival was strongly correlated with hematopoietic recovery [52]C4. Quality nursing combined with health education reduces inflammatory markers (CRP, PCT, IL-6) and accelerates infection control [15]A1b. Older donor age (≥40 years) in unrelated BMT is associated with higher fatal infection (13.7% vs 7.5%) [63]B2b.
Clonal Evolution and Malignancy
Transformation to MDS or AML is a feared late complication. In an EBMT analysis of 270 patients transplanted for post-AA myeloid neoplasms, 5-year overall survival was 64%, with 5-year non-relapse mortality of 34% for MDS and 19% for AML [9]B2b. Short telomeres at diagnosis inversely correlate with the probability of developing a cytogenetically abnormal clone, directly implicating telomere dysfunction in malignant evolution [68]B2b. Among patients treated with eltrombopag for moderate AA, 2 of 34 developed non-chromosome 7 cytogenetic abnormalities without dysplasia [62]C4. Clonal hematopoiesis is frequent: somatic mutations were present in 30% at baseline, rising to 55% at 6 months and 80% at 24 months after immunosuppression with or without eltrombopag [67]A1b.
Thromboembolism with TPO-RA
Thromboembolic events occur with both eltrombopag and romiplostim. The incidence per 100 patient-years ranges from 3.1 to 4.2 with romiplostim and is 2.9 with eltrombopag [41]D5. Events are not associated with thrombocytosis; 30-50% occur at platelet counts <50×10⁹/L. Cerebrovascular and myocardial events predominate, especially in patients >70 years [41]D5.
Bone Marrow Fibrosis
Non-progressive reticulin fibrosis (MF-1) develops in 10-50% of patients on TPO-RA; moderate fibrosis (MF-2) occurs in ~18% at a median of 2.5 years. Severe fibrosis (MF-3) or collagen fibrosis is rare [41]D5.
Cataract and Transaminitis
Cataracts developed in 9% of patients on eltrombopag in the EXTEND study over up to 8 years; 5% were severe [41]D5. Transaminitis occurs in up to 10%, is mostly asymptomatic, and reversible with dose interruption [41]D5.
Androgen Toxicity
In the largest EBMT cohort of androgen use in BMF, organ-specific toxicity was manageable, with low rates of solid and hematologic malignancies [4]B2b.
Graft Failure and GVHD
For haploidentical BMT with posttransplant , graft failure occurred in 11% of patients, and overall survival was 94% at 1 and 2 years [11]B2b. Older donor age (≥40 years) was associated with higher rates of primary engraftment failure (9.7% vs 5.0%) and acute GVHD (27.1% vs 19.7%) [63]B2b. In TCRαβ/CD19-depleted haploidentical HSCT, overall graft failure incidence was 30.4%, with most cases successfully retransplanted; TRM was 8.5% [5]B2b.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Infection (fatal) | 13.7% with older donor [63]B2b | G-CSF, antimicrobial prophylaxis | Granulocyte transfusions, quality nursing [52]C4[15]A1b |
| Clonal evolution to MDS/AML | 5-year OS 64% post-transplant [9]B2b | Monitor telomere length [68]B2b | HSCT with reduced intensity conditioning [9]B2b |
| Thromboembolism (TPO-RA) | 3-4 per 100 patient-years [41]D5 | Correct modifiable risk factors | Anticoagulation if platelets >50×10⁹/L [41]D5 |
| Bone marrow fibrosis (TPO-RA) | MF-1 in 10-50%, MF-2 in 18% [41]D5 | Consider romiplostim if transaminitis | Discontinue if MF-3 or collagen [41]D5 |
| Cataract (eltrombopag) | 9% over 8 years [41]D5 | Ophthalmic exam in at-risk patients [41]D5 | Dose reduction or discontinuation |
| Transaminitis (eltrombopag) | Up to 10% [41]D5 | Monitor LFTs monthly first year [41]D5 | Dose interruption, reduction |
| Graft failure | 11% (haplo) to 30% (TCRαβ-depleted) [11]B2b[5]B2b | TBI dose 400 cGy [11]B2b | Second HSCT [11]B2b[5]B2b |
| Acute GVHD | 11% (haplo) to 27% (older donor) [11]B2b[63]B2b | Posttransplant cyclophosphamide, donor age selection | Standard GVHD therapy |
Pearl: The most common cause of death in SAA remains infection, and hematopoietic recovery, whether from IST, TPO-RA, or transplant, is the strongest predictor of survival from severe infections. Short telomeres at diagnosis provide a biomarker for risk of clonal evolution to MDS/AML [68]B2b.
12. Prognosis & Natural History
No articles were found for this section.
Pearl: Prognosis & Natural History is a core element of this topic; weigh it against the sections above.
13. Special Populations & Pregnancy
- ▸Pediatric AA requires age-adjusted eltrombopag dosing (25 mg/d for age 1-<6 years, 50 mg/d for 6-<18 years) and pre-HSCT iron overload assessment (ferritin >2500 ng/mL associated with worse survival).
- ▸Pregnancy in AA/PNH carries high maternal (8% mortality) and fetal (4% mortality) risks; prophylactic anticoagulation is recommended during pregnancy and postpartum.
- ▸Eltrombopag is a viable option for elderly patients with AA who are ineligible for ATG or HSCT, with transfusion independence rates of 46% at 6 months.
Given the prognostic heterogeneity across age groups and physiological states, management must be tailored for special populations. The following sections highlight key modifications for pediatric, pregnant, and elderly patients with aplastic anemia (AA) or pure red cell aplasia (PRCA).
Pediatrics
Pediatric AA differs from adult disease in response patterns, long-term outcomes, and the need to consider inherited bone marrow failure (BMF) syndromes. The North American Pediatric Aplastic Anemia Consortium (NAPAAC) study of 314 children treated with horse antithymocyte globulin (hATG) plus (CyA) reported a 71.2% objective response rate, with 59.8% achieving complete response and 5-year overall survival of 93% [46]B2b. However, event-free survival without subsequent treatment was only 64% at 5 years, underscoring the need for sustained remission strategies [46]B2b.
For relapsed/refractory disease, allogeneic hematopoietic stem cell transplantation (HSCT) provides superior event-free survival compared with a second course of immunosuppressive therapy (IST): HR = 0.19 (95% CI 0.08-0.47; P = 0.0003) [46]B2b.
Eltrombopag dosing differs by age: in the ESCALATE trial, the starting dose was 25 mg/day for children aged 1 to <6 years and 50 mg/day for those aged 6 to <18 years, with dose modifications up to a maximum of 150 mg/day to achieve a target platelet count of 50-200 × 10⁹/L [44]C4. Adding eltrombopag to IST in treatment-naïve children with severe AA (SAA) increased the complete response rate from 12% to 31% without improving overall survival [60]A1b. The most common adverse events were liver function test abnormalities (bilirubin increased 43.1%, ALT increased 37.3%) [44]C4.
Predictors of IST response in children include:
- Lower white blood cell count (<2.0 × 10⁹/L) [74]B2b
- Shorter interval between diagnosis and therapy [74]B2b
- Male sex [74]B2b
- Presence of a minor paroxysmal nocturnal hemoglobinuria (PNH) clone and longer telomere length [72]B2b
Iron overload before HSCT is a critical risk: pre-HSCT ferritin >2500 ng/mL was associated with decreased 3-year overall survival (HR 2.31; 95% CI 1.06-5.04) and increased bacteremia (HR 3.33; 95% CI 1.72-6.44) [26]B2b. Liver iron concentration was not independently predictive [26]B2b.
Late effects after pediatric HSCT for AA include a 30-year survival of 82% for acquired AA and 58% for , with (GVHD) and Fanconi anemia negatively impacting survival [81]B2b. Malignancy developed in 18 of 152 acquired AA survivors (fatal in 4) [81]B2b. -based conditioning allowed normal growth, development, and pregnancies with mostly normal offspring [81]B2b.
Inherited BMF syndromes must be excluded, as they can present as cryptic AA [78]D5. For Fanconi anemia, HSCT should be offered at a younger age (<10 years) with a well-matched donor to optimize outcomes [79]B3b.
Pregnancy
Pregnancy in women with AA or PNH carries high maternal and fetal risks. In a French series of 27 pregnancies in women with PNH (without eculizumab), maternal complications occurred in 95% of cases, predominantly cytopenias requiring transfusions [83]C4. Two cases of severe AA (de novo or relapse) were recorded [83]C4. No thrombotic events occurred during pregnancy, but postpartum thrombosis occurred in 16% (4 of 27 cases), with 2 fatal events (maternal mortality 8%) [83]C4. Preterm delivery occurred in 29% and birth weight <3 kg in 53%; fetal mortality was 4% [83]C4. Prophylactic anticoagulation is recommended during pregnancy and for 6 weeks postpartum [83]C4.
For women who achieve pregnancy after HSCT for AA (e.g., cyclophosphamide-based conditioning), outcomes are reassuring: pregnancies with mostly normal offspring have been reported [81]B2b.
Management points:
- Close monitoring of blood counts; transfusions as needed for cytopenias.
- Antithrombotic prophylaxis (low-molecular-weight ) during pregnancy and postpartum [83]C4.
- Avoid eltrombopag and immunosuppressive agents (e.g., antithymocyte globulin, cyclosporine) during pregnancy unless absolutely necessary; limited safety data exist.
- Multidisciplinary care including hematology, maternal-fetal medicine, and neonatology.
Elderly
Older patients with AA are often ineligible for intensive IST or HSCT due to comorbidities. Eltrombopag, a thrombopoietin receptor agonist, offers a manageable alternative. In a retrospective French study of 46 patients (including those unfit for ATG), eltrombopag (median daily dose 150 mg) produced hematologic improvement in 64% of ATG-naïve and 74% of relapsed/refractory patients, with transfusion independence rates of 46% at 6 months [51]C4. Hemoglobin improved by a median of 3 g/dL and platelet count by 42 × 10⁹/L [51]C4.
Key considerations for elderly patients:
- Assess comorbidities (cardiac, renal, hepatic) before initiating IST or eltrombopag.
- Monitor for drug interactions (e.g., with , anticoagulants).
- HSCT is rarely offered; if considered, reduced-intensity conditioning may be used, but data in this population are limited.
Pearl: In children with SAA, adding eltrombopag to standard IST increases complete response rate but does not improve survival; its greatest benefit is seen in moderate SAA, not very severe disease [60]A1b. In elderly patients unfit for ATG, eltrombopag monotherapy can achieve transfusion independence in nearly half of patients [51]C4.
14. Prevention, Screening & Surveillance
- ▸PNH clone screening (≥0.1% on granulocytes) at diagnosis differentiates acquired from inherited BMF with high sensitivity and specificity [27][86].
- ▸Telomere length by flow-FISH should be performed in all newly diagnosed AA patients; 22.4% of those with shortened telomeres harbor a pathogenic TBD variant [95].
- ▸Post-transplant surveillance for subsequent neoplasms is critical, with an 11-fold increased risk (SIR 11) compared to the general population [88].
Beyond pregnancy-specific considerations, prevention and surveillance in bone marrow failure syndromes span three domains: primary avoidance of triggers, early detection of complications, and long-term monitoring for clonal evolution.
Screening for Paroxysmal Nocturnal Hemoglobinuria Clones
Screening for PNH clones at the time of an AA diagnosis is recommended by national and international guidelines [86]A1c. Flow cytometry with a threshold of ≥0.1% on granulocytes is the standard; in one large validation cohort, a PNH clone was detected in 46.2% of acquired AA patients at diagnosis [27]B3b. The presence of a PNH clone ≥0.1%, combined with absence of morphological abnormalities, achieves a positive predictive value of 97.8% (95% CI 95.7-99) for acquired AA [27]B3b. PNH clone size should be monitored regularly by flow cytometry, with on-demand testing if lactate dehydrogenase or reticulocyte count rises, or if thrombotic symptoms develop [86]A1c.
Telomere Length Screening and Germline Testing
Telomere length measured by flow-FISH is a powerful functional in vivo screening tool for an underlying telomere biology disorder (TBD) and should be performed in every newly diagnosed patient with AA [95]B2b. Telomeres below the 1st percentile for age are highly sensitive and specific for [84]B3b. In a prospective cohort, 22.4% of patients with shortened telomeres by standard screening criteria had a pathogenic TBD-associated gene variant [95]B2b. When a germline mutation is identified, cascade testing of first-degree relatives is essential, as undiagnosed carriers may serve as stem cell donors [84]B3b. The diagnostic algorithm developed by Kaphan et al. incorporates morphological abnormalities, PNH clone, and acute onset of cytopenia to differentiate acquired from inherited BMF, achieving a sensitivity of 95.7% and specificity of 91.8% in validation [27]B3b.
Pre-Transplant Risk Stratification
Before hematopoietic cell transplantation, risk stratification can reduce preventable complications. High-risk features for transplant-associated thrombotic microangiopathy (TA-TMA) include age ≥10 years, myeloablative conditioning with total body irradiation, HLA mismatch, and diagnosis of severe aplastic anemia; in high-risk patients, combination prophylaxis with eicosapentaenoic acid and N-acetylcysteine reduced the 1-year cumulative incidence of TA-TMA from 28.2% to 4.5% [89]B3b. Bloodstream infections during conditioning are more likely in patients receiving antithymocyte globulin (ATG) - 96.5% of BSI cases occurred with ATG-based conditioning - and those with AA, HCT-CI ≥2, or preconditioning neutropenia ≥7 days; surveillance for carbapenem-resistant organisms and targeted prophylaxis is warranted [96]B3b.
Post-Transplant Surveillance
Long-term survivors require vigilant monitoring for subsequent neoplasms. In a CIBMTR registry study of 6028 children undergoing allogeneic HCT for nonmalignant diseases, the standardized incidence ratio for subsequent neoplasms was 11 (95% CI 8.9-13.9), with the highest risk in and marrow failure syndromes [88]B3b. Oropharyngeal, skin, liver, and thyroid tumors emerge after 5 years, mandating annual dermatologic and otolaryngologic examination [88]B3b. Cytomegalovirus reactivation is a persistent threat; chronic GVHD is an independent risk factor for CMV infection after haploidentical HSCT, and strengthened monitoring of CMV-DNA is recommended [97]B3b. Graft rejection should be suspected when fever is accompanied by rising CXCL9, BAFF, and sC5b-9 levels [87]B3b.
Patient Education
Patients should be counseled to avoid drugs with known association with AA (identified in 20.8% of cases in one epidemiologic study [54]B3b) and to report fever, bleeding, or new symptoms promptly. For inherited cases, genetic counseling and family screening are mandatory. Vaccination strategies should follow standard guidelines for immunocompromised hosts, though specific recommendations for this population are not addressed in the provided evidence.
Pearl: In every new diagnosis of aplastic anemia, perform flow cytometry for PNH clone and telomere length measurement; a PNH clone ≥0.1% plus absence of morphological abnormalities essentially rules out inherited bone marrow failure (PPV 97.8%) [27]B3b[95]B2b.
| Domain | Test | Target Population | Frequency | Guideline Source |
|---|---|---|---|---|
| PNH clone | High-sensitivity flow cytometry (≥0.1% threshold) | All new AA diagnoses | At diagnosis, then on-demand with LDH rise or symptoms | [86]A1c[98]C4 |
| Telomere biology disorder | Flow-FISH telomere length | All new AA diagnoses | At diagnosis | [95]B2b |
| Germline mutation | Targeted NGS panel for IBMF genes | AA patients with shortened telomeres, morphological abnormalities, or family history | At diagnosis; cascade testing for relatives | [95]B2b[27]B3b |
| Subsequent neoplasms | Annual dermatologic & otolaryngologic exam | All HCT survivors, especially Fanconi anemia & marrow failure syndromes | Annually after 5 years post-HCT | [88]B3b |
| CMV reactivation | CMV-DNA PCR | Post-HSCT patients | Weekly during first 100 days, then as clinically indicated | [97]B3b |
| Graft rejection | CXCL9, BAFF, sC5b-9, fever kinetics | Patients with febrile episodes post-HCT | At time of fever | [87]B3b |
References
- [1]
Kim TO, Despotovic J, Lambert MP. “Eltrombopag for use in children with immune thrombocytopenia.” Blood advances (2018). PMID: 29487060 ↗
L5RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications, 13. Special Populations & Pregnancy - [2]
Tichelli A, de Latour RP, Passweg J et al.. “Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation.” Haematologica (2019). PMID: 31582549 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors - [3]
Vaht K, Göransson M, Carlson K et al.. “Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011.” Haematologica (2017). PMID: 28751565 ↗
L2PROSPECTIVE_COHORTCited in: 3. Epidemiology, Etiology & Risk Factors - [4]
Pagliuca S, Kulasekararaj AG, Eikema DJ et al.. “Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation.” Haematologica (2024). PMID: 37199126 ↗
L2PROSPECTIVE_COHORTCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications - [5]
Merli P, Pagliara D, Galaverna F et al.. “TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders.” Blood advances (2022). PMID: 34592755 ↗
L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications - [6]
da Fonseca AR, Justino CC, Campos de Molla V et al.. “Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates.” Blood advances (2025). PMID: 39693508 ↗
L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors - [7]
Maluf E, Hamerschlak N, Cavalcanti AB et al.. “Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study.” Haematologica (2009). PMID: 19734415 ↗
L3NON_RANDOMIZED_TRIALCited in: 3. Epidemiology, Etiology & Risk Factors - [8]
Hama A, Takahashi Y, Muramatsu H et al.. “Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine.” Haematologica (2015). PMID: 26273061 ↗
L2NON_RANDOMIZED_TRIALCited in: 3. Epidemiology, Etiology & Risk Factors - [9]
Prata PH, Eikema DJ, Piepenbroek B et al.. “Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.” Haematologica (2025). PMID: 40605711 ↗
L2RETROSPECTIVE_COHORTCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications - [10]
Kamio T, Ito E, Ohara A et al.. “Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group.” Haematologica (2011). PMID: 21422115 ↗
L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors - [11]
DeZern AE, Zahurak ML, Symons HJ et al.. “Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide.” Blood advances (2020). PMID: 32343796 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications - [12]
Scheinberg P. “Activity of eltrombopag in severe aplastic anemia.” Blood advances (2018). PMID: 30425070 ↗
L5NARRATIVE_REVIEWCited in: 3. Epidemiology, Etiology & Risk Factors - [13]
Andresen F, Yoshimi A, Bader P et al.. “Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years.” Blood advances (2026). PMID: 41558034 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [14]
Dale DC, Bolyard AA, Shannon JA et al.. “Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.” Blood advances (2022). PMID: 35476051 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [15]
Shen W, Wei F. “Clinical impact of quality nursing combined with health education pathway on quality of life and sleep in severe aplastic anemia patients complicated with infection: a randomized clinical trial.” Frontiers in medicine (2025). PMID: 40842537 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications - [16]
Wang L, Ye L, Zhao X et al.. “Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study.” Blood cancer journal (2025). PMID: 40617806 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors - [17]
Kirschner M, Maurer A, Wlodarski MW et al.. “Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita.” Leukemia (2018). PMID: 29749397 ↗
L3OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [18]
Xue Y, She S, Sun S et al.. “The complications of cyclosporine a in pediatric use and its effectiveness in treating pediatric congenital heart diseases-a meta analysis in combined with a retrospective clinical study.” Frontiers in pharmacology (2025). PMID: 41394124 ↗
L1SR_COHORTCited in: 3. Epidemiology, Etiology & Risk Factors - [19]
Zhao X, Xu Z, Sun Y et al.. “A prospective, open, single-arm clinical trial of fludarabine- cyclophosphamide-porcine anti-lymphocyte globulin conditioning combined with matched sibling donor hematopoietic stem cell transplantation in the treatment of severe aplastic anemia.” Clinical and experimental medicine (2026). PMID: 42118371 ↗
L2NON_RANDOMIZED_TRIALCited in: 3. Epidemiology, Etiology & Risk Factors - [20]
Zhang X, Pan L, Zhao Y et al.. “Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II study.” Experimental hematology & oncology (2026). PMID: 41796372 ↗
L2NON_RANDOMIZED_TRIALCited in: 3. Epidemiology, Etiology & Risk Factors - [21]
Cuccuini W, Collonge-Rame MA, Auger N et al.. “Cytogenetics in the management of bone marrow failure syndromes: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).” Current research in translational medicine (2023). PMID: 38016422 ↗
L1GUIDELINECited in: 6. Staging, Risk Stratification & Prognostic Scoring - [22]
Su S, Zhou H, Wang Z et al.. “When intestinal ulceration meets hematologic malignancies: clinical features and mortality from a pooled individual-patient data systematic review.” Frontiers in immunology (2026). PMID: 42292435 ↗
L1SR_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [23]
Yafour N, Bekadja MA, El Bejjaj I et al.. “[Acquired severe aplastic anemia in emerging countries: Management from allogeneic hematopoietic cell transplantation indication until post-transplant follow-up SFGM-TC].” Bulletin du cancer (2024). PMID: 39227199 ↗
L1GUIDELINECited in: 6. Staging, Risk Stratification & Prognostic Scoring - [24]
Wen X, Xiao L, Li D et al.. “Development and validation of a nomogram for early prognostic prediction in childhood aplastic anemia receiving cyclosporine monotherapy.” Pediatric research (2026). PMID: 42177308 ↗
L2RETROSPECTIVE_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 14. Prevention, Screening & Surveillance - [25]
Lin MH, Xu ZL, Chang YJ et al.. “Dynamic immune reconstitution and clinical outcomes in different chimerism statuses of HLA-matched transplantation for severe aplastic anemia.” Stem cells translational medicine (2026). PMID: 41894587 ↗
L2RETROSPECTIVE_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [26]
Gibson NM, Nguyen N, Amaral S et al.. “Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders.” Blood advances (2026). PMID: 41637630 ↗
L2RETROSPECTIVE_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy - [27]
Kaphan E, Walter-Petrich A, Larcher L et al.. “Recursive Partitioning to Differentiate Acquired From Inherited Bone Marrow Failure Syndromes.” American journal of hematology (2025). PMID: 40955622 ↗
L3COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 14. Prevention, Screening & Surveillance - [28]
Tan Z, Hu J, Zhao Y et al.. “The Optimal Adjuvant Reinfusion Strategy for Aplastic Anemia: Umbilical Cord Blood or Mesenchymal Stem Cells? A Single-Center Retrospective Study.” Transplantation and cellular therapy (2025). PMID: 40915607 ↗
L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [29]
Han L, Shi X, Wang S et al.. “Complex association of mean corpuscular volume and outcomes in patients with aplastic anemia treated with cyclosporine A plus androgen or cyclosporine A alone.” Clinical and experimental medicine (2025). PMID: 40377721 ↗
L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [30]
Lin MH, Sun W, Huang XJ et al.. “Incidence, risk factors and clinical outcomes of primary prolonged isolated thrombocytopenia following haploidentical transplantation for severe aplastic anemia.” Cytotherapy (2025). PMID: 40347202 ↗
L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [31]
Qi Y, Liu X, Ding Z et al.. “A potential predictive model based on machine learning and CPD parameters in elderly patients with aplastic anemia and myelodysplastic neoplasms.” BMC medical informatics and decision making (2024). PMID: 39695587 ↗
L3RETROSPECTIVE_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [32]
Liu L, Zhang D, Fu Q et al.. “Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.” Clinical and experimental medicine (2023). PMID: 37087521 ↗
L3RETROSPECTIVE_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [33]
Zhang J, Liu T, Duan Y et al.. “Single-cell analysis highlights a population of Th17-polarized CD4+ naïve T cells showing IL6/JAK3/STAT3 activation in pediatric severe aplastic anemia.” Journal of autoimmunity (2023). PMID: 37001436 ↗
L4RETROSPECTIVE_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [34]
Devillier R, Eikema DJ, Dufour C et al.. “Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT.” Haematologica (2023). PMID: 36951165 ↗
L2RETROSPECTIVE_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [35]
Chen D, Yuan Z, Guo Y et al.. “Prognostic Impact of Quantifying Sarcopenia and Adipopenia by Chest CT in Severe Aplastic Anemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation.” Academic radiology (2022). PMID: 36379814 ↗
L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [36]
Nguyen TH, Satwani P, Kumar D et al.. “Systemic T-cell activation and IFN-γ activity in indeterminate severe hepatitis are reminiscent of hemophagocytic lymphohistiocytosis: Implications for T-cell- and IFN-γ-directed therapies.” The Journal of allergy and clinical immunology (2024). PMID: 39278359 ↗
L4CASE_CONTROLCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [37]
Vissers LTW, van Ostaijen-Ten Dam MM, Melsen JE et al.. “Potential role of B- and NK-cells in the pathogenesis of pediatric aplastic anemia through deep phenotyping.” Frontiers in immunology (2024). PMID: 39229270 ↗
L4CASE_CONTROLCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [38]
Li J, Li X, Cai L et al.. “Prognostic value of pre-treatment PNH clone among the patients with aplastic anemia: a meta-analysis.” Hematology (Amsterdam, Netherlands) (2023). PMID: 37191286 ↗
L2SR_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [39]
Chen D, Mo W, Gao L et al.. “Sarcopenia-associated CD8+ T-cell reconstitution predicts poor outcomes in severe aplastic anemia after hematopoietic stem cell transplantation.” Annals of hematology (2026). PMID: 42213175 ↗
L2RETROSPECTIVE_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [40]
Tolunay AÜ, Gündeşlioğlu ÖÖ, Yeşiloğlu A et al.. “Diagnosis, management, and clinical outcomes of childhood invasive aspergillosis.” BMC pediatrics (2026). PMID: 42185850 ↗
L4RETROSPECTIVE_COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [41]
Ghanima W, Cooper N, Rodeghiero F et al.. “Thrombopoietin receptor agonists: ten years later.” Haematologica (2019). PMID: 31073079 ↗
L5RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications - [42]
Olnes MJ, Scheinberg P, Calvo KR et al.. “Eltrombopag and improved hematopoiesis in refractory aplastic anemia.” The New England journal of medicine (2012). PMID: 22762314 ↗
L4NON_RANDOMIZED_TRIALCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [43]
Durrani J, Chen LN, Shalhoub RN et al.. “Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy.” Blood advances (2025). PMID: 40085951 ↗
L2PROSPECTIVE_COHORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [44]
Shimamura A, Maschan A, Bennett C et al.. “Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial.” Blood advances (2025). PMID: 40315366 ↗
L4NON_RANDOMIZED_TRIALCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy - [45]
Olivieri D, Othus M, Vo P et al.. “Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.” Blood advances (2026). PMID: 41637641 ↗
L2RETROSPECTIVE_COHORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance - [46]
Rogers ZR, Nakano TA, Olson TS et al.. “Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study.” Haematologica (2019). PMID: 30948484 ↗
L2NON_RANDOMIZED_TRIALCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy - [47]
Cappellini MD, Porter J, El-Beshlawy A et al.. “Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.” Haematologica (2009). PMID: 19951979 ↗
L2NON_RANDOMIZED_TRIALCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [48]
Lee JW, Yoon SS, Shen ZX et al.. “Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study.” Haematologica (2013). PMID: 23585526 ↗
L2NON_RANDOMIZED_TRIALCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [49]
Prabahran A, Wu L, Manley AL et al.. “Mature megakaryocytes acquire immune characteristics in a mouse model of aplastic anemia.” Blood advances (2025). PMID: 40086077 ↗
L5CASE_CONTROLCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [50]
Zaimoku Y, Patel BA, Shalhoub R et al.. “Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag.” Haematologica (2022). PMID: 33910334 ↗
L2COHORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [51]
Lengline E, Drenou B, Peterlin P et al.. “Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.” Haematologica (2017). PMID: 29170252 ↗
L4COHORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications, 13. Special Populations & Pregnancy - [52]
Quillen K, Wong E, Scheinberg P et al.. “Granulocyte transfusions in severe aplastic anemia: an eleven-year experience.” Haematologica (2009). PMID: 19996117 ↗
L4COHORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications - [53]
Scheinberg P, Marte M, Nunez O et al.. “Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.” Haematologica (2010). PMID: 20595102 ↗
L4COHORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [54]
Montané E, Ibáñez L, Vidal X et al.. “Epidemiology of aplastic anemia: a prospective multicenter study.” Haematologica (2008). PMID: 18322256 ↗
L3CASE_CONTROLCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance - [55]
Kuwana M, Kurata Y, Fujimura K et al.. “Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by multi-center prospective study.” Journal of thrombosis and haemostasis : JTH (2006). PMID: 16961601 ↗
L2COHORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [56]
Feng X, Scheinberg P, Samsel L et al.. “Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura.” Journal of thrombosis and haemostasis : JTH (2012). PMID: 22537155 ↗
L4CASE_CONTROLCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [57]
Fattizzo B, Gurnari C, Cassanello G et al.. “Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study.” Leukemia (2023). PMID: 37794100 ↗
L2COHORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [58]
Liu L, Zhang Y, Jiao W et al.. “Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia.” Leukemia (2020). PMID: 32591644 ↗
L2COHORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [59]
Pigneux A, Béné MC, Guardiola P et al.. “Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 28129526 ↗
L1RCTCited in: 11. Complications - [60]
Goronkova O, Novichkova G, Salimova T et al.. “Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia.” Blood advances (2023). PMID: 35446936 ↗
L1RCTCited in: 11. Complications, 13. Special Populations & Pregnancy - [61]
Giné E, de la Cruz F, Jiménez Ubieto A et al.. “Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35030036 ↗
L4NON_RANDOMIZED_TRIALCited in: 11. Complications - [62]
Fan X, Desmond R, Winkler T et al.. “Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias.” Blood advances (2020). PMID: 32330244 ↗
L4NON_RANDOMIZED_TRIALCited in: 11. Complications - [63]
Arai Y, Kondo T, Yamazaki H et al.. “Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia.” Haematologica (2016). PMID: 26858357 ↗
L2PROSPECTIVE_COHORTCited in: 11. Complications - [64]
Helby J, Nordestgaard BG, Benfield T et al.. “Shorter leukocyte telomere length is associated with higher risk of infections: a prospective study of 75,309 individuals from the general population.” Haematologica (2017). PMID: 28522577 ↗
L2COHORTCited in: 11. Complications - [65]
Schifferli A, Heiri A, Imbach P et al.. “Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP.” Blood advances (2021). PMID: 33710335 ↗
L2OTHERCited in: 11. Complications - [66]
Schmied L, Olofsen PA, Lundberg P et al.. “Secondary CNL after SAA reveals insights in leukemic transformation of bone marrow failure syndromes.” Blood advances (2020). PMID: 33166403 ↗
L4OTHERCited in: 11. Complications - [67]
Kaya DE, Cook R, Iacobelli S et al.. “Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.” NEJM evidence (2026). PMID: 42047558 ↗
L1RCTCited in: 11. Complications - [68]
Calado RT, Cooper JN, Padilla-Nash HM et al.. “Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.” Leukemia (2011). PMID: 22005790 ↗
L2OTHERCited in: 11. Complications - [69]
Matsui WH, Brodsky RA, Smith BD et al.. “Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes.” Leukemia (2006). PMID: 16437138 ↗
L3OTHERCited in: 11. Complications - [70]
Babushok DV, DeZern AE, de Castro CM et al.. “Modified Delphi panel consensus recommendations for management of severe aplastic anemia.” Blood advances (2024). PMID: 38669341 ↗
L5GUIDELINECited in: 13. Special Populations & Pregnancy - [71]
Imi T, Katagiri T, Hosomichi K et al.. “Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia.” Blood advances (2018). PMID: 29720492 ↗
L4NON_RANDOMIZED_TRIALCited in: 13. Special Populations & Pregnancy - [72]
Narita A, Muramatsu H, Sekiya Y et al.. “Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia.” Haematologica (2015). PMID: 26315930 ↗
L2NON_RANDOMIZED_TRIALCited in: 13. Special Populations & Pregnancy - [73]
Young NS, Calado RT, Scheinberg P. “Current concepts in the pathophysiology and treatment of aplastic anemia.” Blood (2006). PMID: 16778145 ↗
L5CASE_SERIESCited in: 13. Special Populations & Pregnancy - [74]
Yoshida N, Yagasaki H, Hama A et al.. “Predicting response to immunosuppressive therapy in childhood aplastic anemia.” Haematologica (2011). PMID: 21273269 ↗
L2RETROSPECTIVE_COHORTCited in: 13. Special Populations & Pregnancy - [75]
Gerull S, Stern M, Apperley J et al.. “Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation.” Haematologica (2013). PMID: 23894010 ↗
L2COHORTCited in: 13. Special Populations & Pregnancy - [76]
Krell PF, Reuther S, Fischer U et al.. “Next-generation-sequencing-spectratyping reveals public T-cell receptor repertoires in pediatric very severe aplastic anemia and identifies a β chain CDR3 sequence associated with hepatitis-induced pathogenesis.” Haematologica (2013). PMID: 23716544 ↗
L4CASE_CONTROLCited in: 13. Special Populations & Pregnancy - [77]
Locatelli F, Strahm B. “How I treat myelodysplastic syndromes of childhood.” Blood (2018). PMID: 29438960 ↗
L5NARRATIVE_REVIEWCited in: 13. Special Populations & Pregnancy - [78]
Dokal I, Tummala H, Vulliamy T. “Inherited bone marrow failure in the pediatric patient.” Blood (2022). PMID: 35605178 ↗
L5OTHERCited in: 13. Special Populations & Pregnancy - [79]
Lum SH, Eikema DJ, Piepenbroek B et al.. “Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia.” Blood (2024). PMID: 38968140 ↗
L3OTHERCited in: 13. Special Populations & Pregnancy - [80]
Stieglitz E, Loh ML. “Pediatric MDS: GATA screen the germline.” Blood (2016). PMID: 26989184 ↗
L5NARRATIVE_REVIEWCited in: 13. Special Populations & Pregnancy - [81]
Sanders JE, Woolfrey AE, Carpenter PA et al.. “Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia.” Blood (2011). PMID: 21653322 ↗
L2OTHERCited in: 13. Special Populations & Pregnancy - [82]
Wlodarski MW, Hirabayashi S, Pastor V et al.. “Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents.” Blood (2015). PMID: 26702063 ↗
L2OTHERCited in: 13. Special Populations & Pregnancy - [83]
de Guibert S, Peffault de Latour R, Varoqueaux N et al.. “Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience.” Haematologica (2011). PMID: 21606169 ↗
L4CASE_SERIESCited in: 13. Special Populations & Pregnancy - [84]
Alter BP, Rosenberg PS, Giri N et al.. “Telomere length is associated with disease severity and declines with age in dyskeratosis congenita.” Haematologica (2011). PMID: 22058220 ↗
L3NON_RANDOMIZED_TRIALCited in: 14. Prevention, Screening & Surveillance - [85]
Bacigalupo A, Socie' G, Lanino E et al.. “Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.” Haematologica (2010). PMID: 20494932 ↗
L3COHORTCited in: 14. Prevention, Screening & Surveillance - [86]
Wong RSM, Ho Jang J, Wong LLL et al.. “Monitoring and Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia in Asia: An Expert Consensus.” International journal of molecular sciences (2024). PMID: 39596227 ↗
L1GUIDELINECited in: 14. Prevention, Screening & Surveillance - [87]
Sabulski A, Myers KC, Bleesing JJ et al.. “Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure.” Blood advances (2021). PMID: 34614507 ↗
L3OTHERCited in: 14. Prevention, Screening & Surveillance - [88]
Kahn JM, Brazauskas R, Tecca HR et al.. “Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases.” Blood advances (2020). PMID: 32396620 ↗
L3OTHERCited in: 14. Prevention, Screening & Surveillance - [89]
Higham CS, Collins G, Shimano KA et al.. “Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.” Blood advances (2021). PMID: 33877298 ↗
L3OTHERCited in: 14. Prevention, Screening & Surveillance - [90]
Kotmayer L, Kennedy AL, Wlodarski MW. “Germline and somatic genetic landscape of pediatric myelodysplastic syndromes.” Haematologica (2025). PMID: 40568716 ↗
L5NARRATIVE_REVIEWCited in: 14. Prevention, Screening & Surveillance - [91]
Giudice V, Banaszak LG, Gutierrez-Rodrigues F et al.. “Circulating exosomal microRNAs in acquired aplastic anemia and myelodysplastic syndromes.” Haematologica (2018). PMID: 29674506 ↗
L3OTHERCited in: 14. Prevention, Screening & Surveillance - [92]
Keel SB, Scott A, Sanchez-Bonilla M et al.. “Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients.” Haematologica (2016). PMID: 27418648 ↗
L4OTHERCited in: 14. Prevention, Screening & Surveillance - [93]
Nováková M, Žaliová M, Suková M et al.. “Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome.” Haematologica (2016). PMID: 27013649 ↗
L2OTHERCited in: 14. Prevention, Screening & Surveillance - [94]
Giudice V, Feng X, Lin Z et al.. “Deep sequencing and flow cytometric characterization of expanded effector memory CD8+CD57+ T cells frequently reveals T-cell receptor Vβ oligoclonality and CDR3 homology in acquired aplastic anemia.” Haematologica (2018). PMID: 29419434 ↗
L3OTHERCited in: 14. Prevention, Screening & Surveillance - [95]
Tometten M, Kirschner M, Meyer R et al.. “Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria.” HemaSphere (2023). PMID: 37096215 ↗
L2PROSPECTIVE_COHORTCited in: 14. Prevention, Screening & Surveillance - [96]
Pan L, Li J, Lin Q et al.. “Incidence, Risk Factors, and Outcomes of Bloodstream Infection during Conditioning Phase before Allogeneic Hematopoietic Stem Cell Transplantation.” Transplantation and cellular therapy (2025). PMID: 40578622 ↗
L3RETROSPECTIVE_COHORTCited in: 14. Prevention, Screening & Surveillance - [97]
Feng J, Zhang X, Tan Z et al.. “Risk factors and clinical outcomes of cytomegalovirus infection following haploidentical hematopoietic stem cell transplantation in patients with aplastic anemia: a single-center retrospective study.” Frontiers in medicine (2025). PMID: 39944817 ↗
L3COHORTCited in: 14. Prevention, Screening & Surveillance - [98]
Spychalska J, Duńska M, Myślińska A et al.. “Diagnostic landscape of first-time cytometric screening for paroxysmal nocturnal hemoglobinuria in Poland in 2013-2022.” Orphanet journal of rare diseases (2024). PMID: 39020342 ↗
L4RETROSPECTIVE_COHORTCited in: 14. Prevention, Screening & Surveillance - [99]
Kim JM, Sunwoo Y, Kim H et al.. “Expanding the Clinical Spectrum of Arboleda-Tham Syndrome: Neuroimaging Findings and Hematologic Manifestations.” Neurology. Genetics (2024). PMID: 42040242 ↗
L4COHORTCited in: 14. Prevention, Screening & Surveillance